DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call

Name	Symbol	Market	Type
Davis Select US Equity	AMEX:DUSA	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

Davis Select US Equity

AMEX:DUSA

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.10	0.24%	42.26	42.59	42.205	42.48	14,336	15:22:12

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

0.10

0.24%

42.26

42.59

42.205

42.48

14,336

15:22:12

DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call

06/08/2009 11:30am

PR Newswire (US)

Davis Select US Equity (AMEX:DUSA)
Historical Stock Chart

From Dec 2019 to Dec 2024

Click Here for more Davis Select US Equity Charts.

WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq GM: DUSA) announces that its corporate highlights and second quarter financial results press release will be issued on Tuesday, August 11 at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Tuesday, August 11 - 8:30 a.m. E.T. If calling from the US or Canada use the following toll-free number: 800.647.4314 Password - DUSA For International callers use 502.498.8422 A recorded replay of the call will be available approximately 15 minutes following the call North American callers 877.863.0350 International callers 858.244.1268 The call will be accessible on our web site approximately four hours following the call at http://www.dusapharma.com/. About DUSA Pharmaceuticals DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan(R) PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(R). DUSA is researching Levulan(R) PDT for the treatment of AKs and the reduction of new non-melanoma skin cancer (NMSC) in chronically immunosuppressed solid organ transplant recipients (SOTRs). In addition, DUSA is supporting research related to oral leukoplakia in collaboration with National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our Web site at http://www.dusapharma.com/. DATASOURCE: DUSA Pharmaceuticals, Inc. CONTACT: Chad Rubin, The Trout Group LLC, +1-646-378-2947, for DUSA Pharmaceuticals, Inc. Web Site: http://www.dusapharma.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

DUSA Davis Select US Equity